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Henry Masur, from the National Institutes of Health,
Bethesda, Maryland, discussed the changing nature of
opportunistic infections (OIs) in HIV-infected persons in the
United States in light of the use of highly active antiretroviral
therapy (HAART). While the incidence of nearly all OIs has
decreased since 1996, several AIDS-related malignancies
have maintained stable incidence rates and will likely
assume greater importance. Complications resulting from
infection with hepatitis C virus (HCV) will become more
prevalent, since as many as 30% of HIV-infected persons are
coinfected with HCV. Several “reconstitution syndromes,”
illnesses attributed to improved T-cell immunity, have been
described as unusual manifestations of OI in the first few
weeks following initiation of HAART. Antimicrobial
resistance is an increasing problem for bacterial and fungal
OIs and threatens to diminish the efficacy of trimethoprim-
sulfamethoxazole against Pneumocystis carinii pneumonia,
although evidence of this effect is incomplete at present. OIs
also occur because many persons remain undiagnosed with
HIV and therefore do not receive appropriate prophylaxis
against OIs. The fact that only a minority of persons receiving
HAART maintain undetectable virus levels for a sustained
period suggests that HAART will not be effective in many of
these patients and that OIs will increase in incidence.
Thira Sirisanthana, from the Chiang Mai Medical School,
Chiang Mai, Thailand, discussed the importance of
Penicillium marneffei (PM) infection among HIV-infected
persons in Southeast Asia. Please see “Penicillium marneffei
Infection in Patients with AIDS” on page 561 for a more
detailed discussion of this topic.
Mark Russo, from Cornell University Medical College,
New York, New York reviewed the consequences of HCV
infection in recipients of solid organ transplants. Approxi-
mately 21,000 solid organ transplants are performed each
year in the United States, and that number is increasing.  In
liver transplantation, persons who receive transplants to
treat liver disease due to chronic hepatitis C may have lower
graft survival, and retransplantation rates may be as high as
20%.  Treatment of hepatitis C with interferon after liver
transplantation has been disappointing, but new formula-
tions and combination therapy with ribavirin may lead to
increased efficacy.  The use of hepatitis C–positive organs in
hepatitis C–infected recipients is being explored. A small
study of patients with chronic hepatitis C undergoing liver
transplantation showed increased graft survival in those who
received a hepatitis C–positive liver, compared with those
who received a hepatitis C–negative liver.
Chronic hepatitis C infection is a health care problem in
recipients of organs other than the liver, such as kidney
transplants.  Although short-term studies of less than 5 years
demonstrate no difference in liver-related illness and death
between kidney transplant recipients with chronic hepatitis
C and those without infection, long-term studies of 10 years or
more show higher illness and death rates from liver disease in
HCV-infected recipients.  Less is known about the effect of
chronic hepatitis C in heart or lung transplant recipients, but
up to 10% of recipients are hepatitis C–positive.  Outcomes in
recipients of these organs and the role of treatment needs to be
further defined.
Louisa Chapman, from the Centers for Disease Control
and Prevention in Atlanta, Georgia, spoke on xenotransplan-
tation and xenogeneic infections. Please see “Xenotransplan-
tation: Benefits and Risks” on page 545 for a more detailed
article on this portion of the panel.
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